A judge's decision to allow 13 plaintiff's witnesses to testify as experts may have swayed GSK plc to announce a settlement in litigation in California state court alleging the firm’s ranitidine-containing Zantac caused the plainitff's bladder cancer and the firm failed to warn of the cancer risk.
The UK pharma, which doesn’t market Zantac OTC in the US but developed and previously manufactured and marketed the heartburn remedy as an Rx product, said it reached a confidential...
The settlement, which dismisses the complaint initially filed in June 2020, was made “to avoid distraction related to protracted litigation in this case,” according to the announcement GSK published on...